Live Breaking News & Updates on Professors Ethem Murat Arsava

Published: Feb 02, 2021
ROCKAWAY, N.J., Feb. 02, 2021 (GLOBE NEWSWIRE) electroCore Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that full enrollment has been achieved for the TR-VENUS study of non-invasive vagal nerve stimulation (nVNS) for the acute treatment of stroke. TR-VENUS is a double blind, randomized, sham-controlled, multi-center clinical trial, conducted at nine major medical centers across Turkey, supported by the Turkish Neurological Society and partially funded through an unrestricted research grant from electroCore.
Stroke is the second highest cause of death and the third leading cause of disability globally . Ischemic stroke, caused by arterial occlusion, is the most common type of stroke. The effectiveness of current management strategies (e.g. rapid reperfusion with intravenous thrombolysis and endovascular thrombectomy) is dependent on time to treatment. Treating stroke quickly and safely is imperative ....

United States , Mehmet Akif Topcuoglu , Jackie Dorsky , Ethem Murat Arsava , Hans Vitzthum , Eric Liebler , Department Of Neurology , Core Inc , Harvard Medical School , European Union , Technology Guidance , Turkish Neurological Society , Hacettepe University , Core Sapphire , Massachusetts General Hospital , Professors Ethem Murat Arsava , Senior Vice President , Cluster Headache , Trigeminal Autonomic Cephalalgias , Hemicrania Continua , Medication Overuse Headache , Medical Technology Guidance , Core Instructions , Coronavirus Disease , Emergency Use , Healthcare Providers ,